New England Journal of Medicine· 2018Q1· Review
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- 4,738citations
- Q1SCImago
- 2018year
Short summary
Immune checkpoint blockade (ICB) therapy, while effective for cancer, causes a wide range of immune-related adverse events (irAEs) that can complicate treatment.
AI-generated from the title and abstract; the full text is not read.
Key points
- Immune checkpoint blockade (ICB) therapy is associated with a wide range of immune-related adverse events (irAEs).
- These irAEs can complicate the effective use of ICB therapy in cancer patients.
- The review surveys the spectrum of irAEs.
- Management strategies for irAEs are discussed.
AI-generated from the title and abstract; the full text is not read.
Abstract
The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and limit its use in patients with cancer. This review surveys the adverse effects and their management.
The authors' abstract, as published at the source. New England Journal of Medicine, 2018 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Oncology
OncologyMedicine